Zilbrysq Market Projected to Grow 21.64% Annually Through 2030 Following FDA Approval for Myasthenia Gravis
核心洞察
The U.S. Zilbrysq (Zilucoplan) market is projected to grow at a CAGR of 21.64% from 2025 to 2030, following FDA approval in October 2023 for anti-AChR antibody-positive generalized myasthenia gravis (搜索).
The once-daily subcutaneous formulation offers a significant advantage over intravenous complement inhibitors, enabling home self-administration and reducing healthcare costs.
Zilbrysq faces limited direct competition in the subcutaneous C5 complement inhibition space, with no biosimilars in development and existing competitors confined to intravenous administration.
The U.S. market for Zilbrysq (Zilucoplan) is experiencing robust growth, with the market size estimated at USD 60.61 million in 2024 and projected to expand at a compound annual growth rate of 21.64% from 2025 to 2030, according to a new market research report. This growth trajectory follows the drug's FDA approval in October 2023 for treating anti-AChR antibody-positive generalized myasthenia gravis (搜索) (gMG).
FDA Approval Accelerates Market Entry
Zilbrysq received FDA approval under orphan drug designation and priority review pathways, accelerating its entry into the U.S. neuromuscular therapeutics space. The therapy targets a specific patient population, with approximately 85% of diagnosed gMG patients testing positive for AChR antibodies (搜索), providing a clear commercial pathway in the rare disease market.
The approval addresses a high unmet need in this rare, chronic condition. Unlike broad-spectrum immunosuppressants, Zilucoplan's selective inhibition of complement C5 (搜索) directly targets the pathophysiologic cascade driving neuromuscular junction damage, offering specificity in a treatment landscape increasingly oriented toward biologics with well-defined molecular targets.
Subcutaneous Formulation Provides Strategic Advantage
The once-daily subcutaneous formulation represents a significant strategic advantage in the U.S. healthcare setting, where patients and payers actively seek alternatives to intravenous therapies requiring frequent clinical visits. Unlike existing C5 inhibitors Soliris or Ultomiris, which require infusions administered in hospital or outpatient infusion centers, Zilbrysq can be self-injected at home using a prefilled syringe.
This approach aligns with growing demand for decentralized chronic disease management, reducing infusion-related costs and improving treatment adherence. The subcutaneous format has enabled rapid integration into payer-preferred pharmacy networks and patient support programs, helping to mitigate initiation barriers and improve real-world outcomes.
Limited Competition in Subcutaneous Space
As of 2024, Zilbrysq faces limited direct competition in the U.S. for subcutaneous C5 complement inhibition, with no biosimilars in development and other approved C5 inhibitors confined to intravenous administration. While newer FcRn (搜索) inhibitors such as Vyvgart and Rozanolixizumab offer differentiated mechanisms, they do not overlap with the complement pathway and are often considered complementary rather than substitutive in refractory cases.
This segmented competitive environment reduces therapeutic redundancy and supports market coexistence, allowing prescribers to tailor therapies based on individual patient profiles and response history. The lack of direct subcutaneous C5 competitors through at least 2030, combined with ongoing investments in real-world data collection and provider education, is expected to preserve Zilbrysq's clinical and economic position in the U.S. rare neurology market.
Market Distribution and Access
The presence of a well-established specialty pharmacy network, favorable commercial insurance coverage, and prescriber familiarity with complement pathway inhibition strengthen Zilbrysq's early market trajectory. In the U.S., where specialty pharmacies dominate the distribution of rare disease biologics, the drug's suitability for both commercial and Medicare populations enhances uptake in a fragmented reimbursement landscape.
The differentiated profile has led to rapid adoption among neurologists treating refractory or corticosteroid-intolerant gMG patients. With gMG recognized as a lifelong condition requiring sustained control, Zilbrysq's targeted mechanism and regulatory protections support premium pricing and long-term payer alignment, solidifying its role in treatment sequencing.